Skip to content

Pfizer to cash in on cardiovascular treatments as heart attack deaths soar

Pharmaceutical giant Pfizer is poised to cash in on new cardiovascular treatments as heart failure cases and related deaths soar around the world.

Pfizer is expanding into drugs for heart inflammation by gaining a dominant grip on the cardiovascular treatment market.

The company has completed the purchase of Arena Pharmaceuticals for $6.7 billion.

Arena Pharma is a market leader in creating drugs to treat immunoinflammatory diseases that are often caused by vaccine injury.

Aamir Malik, Pfizer’s chief business innovation officer, celebrated the news in a statement about the acquisition.

“We believe this transaction represents the best next step for both patients and shareholders,” Malik said.

The move is great news for Pfizer shareholders investors will get paid about the cases of vascular coagulation that have skyrocketed in the last two years.

Conveniently, immunoinflammatory diseases are side effects of Pfizer’s Covid hits.

The company can capitalize on the treatment of these compound health problems created in the vascular systems of millions of people worldwide.

A drug called Etrasimod, which treats inflammatory conditions, is at the center of Pfizer’s acquisition of Arena Pharmaceuticals.

A side effect of Pfizer’s Covid vaccine is spike protein syndromewhich causes chronic inflammation.

Another of the company’s products is called Temanogrel, a drug used to treat microvascular obstruction.

Microvascular obstruction is one of the main problems caused by Pfizer’s shots as it causes myocarditis.

Cases of myocarditisa potentially fatal inflammation of the heart muscle, has skyrocketed worldwide since the release of the Covid mRNA shots.

Myocarditis is listed by the CDC as a known side effect of jabs.

Again, it’s the epitome of problem-reaction-solution Business model

Temanogrel, also known as APD791, is used to treat arterial thrombosis.

Like the Covid shots, Temanogrel it also received fast-track approval from the FDA in 2020, meaning it essentially skipped clinical trials and went straight to market.

In March 2023, the National Institutes of Health (NIH), published the known adverse events following the administration of COVID-19 mRNA vaccines as documented in clinical trials.

The results, published in the National Library of Medicine and the National Center for Biotechnology Information, include a systematic review of “cardiovascular complications, thrombosis, and thrombocytopenia.”

Reports have flooded the system revealing cardiovascular complications arising after the first or second dose of mRNA injections.

Cardiovascular complications listed include: “pericarditis/myopericarditis, myocarditis, hypotension, hypertension, arrhythmia, cardiogenic shock, stroke, myocardial infarction/STEMI, intracranial hemorrhage, thrombosis (deep vein thrombosis, cerebral venous thrombosis, arterial or venous thrombotic eventsportal vein thrombosis, coronary thrombosis, microvascular thrombosis of the small intestine) and pulmonary embolism”.

Arterial thrombosis is the formation of blood clots or “thrombus” within an artery that restricts or blocks blood flow.

It can lead to acute coronary syndrome or stroke, like what we see all over the news athletes, military membersi famous people who was shot and then suffered cardiac arrests or even “died suddenly.”

After acquiring Arena Pharmaceuticals, Pfizer will likely rake in billions of dollars selling treatments for cardiovascular treatments such as heart-related deaths. keep firing.

Arena Senior Vice President Chris Cabell MD issued a statement noting that the company will be able to corner the market:

“With approximately 10 million DHF patient hospital visits expected in the US by 2025 and few viable treatment options, we believe APD418 has the potential to make a significant impact for these patients.”

The company predicts that at least 10 million new patients will suffer from cardiovascular obstructions.

Under the terms of the acquisition, Arena Pharma was valued at $100 in cash per share.

Following the merger, Arena is now a wholly owned subsidiary of Pfizer.

READ MORE: Unvaccinated Amish Death Rates 90 Times Lower Than Rest of America

Share this:


Leave a Reply

Your email address will not be published. Required fields are marked *